List of Therapeutic Companies in Spain - 55

AB-BIOTICS is a leading probiotics player inspired by developing probiotic solutions at the forefront of an expanding field. Whether you are interested in unique, patented strains with characterized mechanisms of action, premium probiotic solutions targeting specific therapeutic areas, or finished products with easily-communicated benefits, our agile approach allows us to adapt to your needs. With science at the heart of everything we do, our strains, blends and market-ready products are supported by robust scientific documentation. Our global footprint gives us a unique view of the ever-changing probiotic landscape enabling us to offer regulatory support in not only supplements, and functional foods but also OTC and medical applications to meet the needs of consumers worldwide.

A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease Modifying Therapies). We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research. We have currently built up a drug candidate portfolio that focuses on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy.

Our mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning. To fulfill our vision, we work with our customers by becoming key technology partners, boosting their discovery workflow with the most innovative solutions. Science, research, innovation, and development are the founding pillars of our company.

AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen.

Affirma Biotech is a privately owned preclinical company that develops new orally available immunotherapeutic drugs for the treatment of severe infections.

Health is the level of functional or metabolic efficiency of a living organism. In humans it is the ability of individuals or communities to adapt and self-manage when facing physical, mental or social challenges.

AntalGenics is a biotechnological company focused on the design and development of new active molecules for biomedical and dermocosmetic applications MISSION To discover and develop innovative leads in the field of sensory neurobiology with pharmaceutical and dermocosmetical applications. VISION To transform our scientific results into products and services for society and to improve the quality of life.

aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept.

Araclon Biotech S.L. is a biotechnology company founded by Pr. Manuel Sarasa. Araclon Biotech is a company dedicated to the research and development of therapies and diagnostic methods to be applied to degenerative diseases, currently focusing on Alzheimer’s disease. At present, Araclon is working on four different projects: The first of these focuses on the diagnosis of Alzheimer’s disease (with a detection kit for beta-amyloid 40 and 42 proteins in blood already patented). The second is centred on Alzheimer’s therapy (immunotherapy based). The third is an emerging project, which attempts to respond to the challenge of predicting Alzheimer’s disease in totally asymptomatic individuals. And finally, a project related to the development of a therapy for the Parkinson’s disease. Our mission To research and develop immunotherapies and diagnostic methods used in the treatment of degenerative diseases. It is our aim to provide effective solutions for such diseases. Our objectives Within the area of degenerative diseases, we are currently focused on Alzheimer’s disease. As such, our initial objectives are: Validation and global marketing of a diagnostic blood test for Alzheimer’s disease. Development of effective immunotherapy against Alzheimer’s disease.

Archivel Farma is a biotech R&D company focused on the development of innovative immunotherapeutic products, notably in sterile, injectable and lyophilised products. Archivel Farma is currently developing, as its own project, RUTI®, a therapeutic vaccine for the treatment of active tuberculosis.

ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. ARTHEx has developed its proprietary technology, the ENTRY ™ platform, that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role. The first investigational product from this platform is ATX-01, an antimiR in preclinical development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000) with no cure, nor approved treatment to date. ATX-01 is a first-in-class disease-modifying therapy that addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis. To learn more about Arthex Biotech, please visit us at www.arthexbiotech.com

Ascil Biopharm is a Drug Delivery System company specialized in Long Acting Injectables (LAI) and devices. Our Research and development is focused in Controlled Release Formulations (CRF) and precision medical devices to enhance efficiency, safety, and patient convenience.

CONNECTA Therapeutics S.L. is a biotechnology company that develops new treatments for CNS unmet medical needs. The company is initially focus on the clinical development of a new “first-in-class” molecule for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are no therapeutic interventions currently available. The molecule was discovered after evaluating more than 30 molecular and cellular targets. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).

deepull is a development-stage clinical diagnostics company focusing on direct from blood sepsis diagnostics. We are based in Barcelona, Spain.

We are ESTEVE, a global pharmaceutical company with one defined mission: improving lives. Founded in 1929 and headquartered in Barcelona, we have a strong international footprint, with affiliates across Spain, Portugal, Italy, Germany, France, the UK, and the USA. As a leader in speciality pharmaceuticals, we focus on creating highly specialized treatments that address significant unmet medical needs. Our expertise extends to Contract Manufacturing, where we produce Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain, Mexico, and China. Driven by our core values—people matter, transparency, and accountability—we’re committed to innovation, quality, and making a meaningful difference in healthcare. Because we care not only about what we do, but also about how we do it. #ESTEVE #AdvancingHealthTogether #Makeitsustainable #Pharmaceuticals #Innovation #SpecialtyPharma #APIs

Evolving Therapeutics was founded in 2023 by sisters and doctors Pilar Domingo-Calap and Marisa Domingo-Calap, with the support of the University of Valencia and the Respiralia Foundation, a non-profit foundation for cystic fibrosis. It is a biotechnology startup focused on the development of innovative solutions against multi-resistant bacteria. Its bacteriophage-based technology offers sustainable and effective alternatives for the diagnosis, treatment and prevention of bacterial infections in human, animal and plant health. Evolving Therapeutics' connection with the University of Valencia has been key in the development of its technology. Through collaboration and knowledge transfer programs , the startup has had access to advanced infrastructure and scientific talent, thus strengthening its capacity to innovate and respond to the challenges posed by antimicrobial resistance.

At Ferrer, we focus on identifying projects with differential value. The R&D team aims to develop and deliver transformative therapeutic solutions for people living with severe and debilitating diseases. Innovation is an inherent part of our pharmaceutical development, and we have always upheld our commitment in searching for and developing new treatment alternatives aimed at addressing unmet medical needs in order to improve the patients' quality of life and creating value for physicians, health systems and society at large. We do this in two main areas: Pulmonary vascular and interstitial lung diseases & Neurological disorders

Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. A leader in essential plasma-derived medicines and other innovative biopharmaceutical solutions.

Highlight, formerly known as Bioncotech Therapeutics S.L, is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Its lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold’ tumors ‘hot’ and therefore visible to the immune system. It has the potential to rescue patients who are resistant to current checkpoint inhibitor therapy. BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors. In addition to in-house research, Highlight Therapeutics has a number of external collaborators, including Merck & Co and UCLA.

Histocell is a clinical-stage biopharmaceutical company, specialized in developing cell therapy medicaments and novel medical devices for regenerative medicine, with a therapeutic approach focus on the control of oxidative stress. We work to improve people’s quality of life by creating new Cell Therapy medicaments. Our headquarters is located at the Bizkaia Science and Technology Park (Spain), with facilities comprising a 65 m2 GMP certified manufacturing room for cell therapy medicinal products, several laboratories for quality control and R&D activities and a 2000 m2 medical device manufacturing plant. Our team meets the maximum quality standards through GMP and ISO 9001/2000 certifications. Company's pipeline includes medical devices for promotion of Natural Wound Healing (Reoxcare® , Vexoderm®), Dermatologic Tissue Regeneration (Histoessence®, Wharton Gel Complex®, Neofibrin®) as well as Cell Therapy programs based on adipose derived mesenchymal stem cells (AMSC) for Bone regeneration and based on HC016 cellular product (proprietary technology) for Acute Spinal Cord Injury and Lung disease. Finally, Histocell, as an authorized ATMP manufacturing laboratory, offers Contract Manufacturing Services for both GMP and GMP-like manufacturing of cell therapy products.

IDP Pharma is a drug discovery company that develops first-in-class medicines (New Chemical Entities) directed to a novel class of therapeutic targets, intrinsically disordered proteins (IDPs). We are currently focused on exploiting new mechanisms of action to treat cancer diseases. Our efforts are directed towards promoting a real shift in cancer therapies to improve the lives of patients. To this end, we have built an extraordinary committed team of experts in the field, supported by a professional advisory board, including IDPs and diseases experts, and business professionals.

INMUNOTEK is a pharma company which researches, develops, manufactures and distributes therapeutic vaccines in the fields of allergy, infectious diseases and cancer. In addition, the company develops, manufactures and sells medical devices. INMUNOTEK was founded in 1992 with the mission of improving the quality of life of patients and providing value to healthcare professionals, by creating innovative, safe and effective products. INMUNOTEK's products are sold in both Spain and in more than 50 other countries around the world through our subsidiaries, sales offices and exclusive distributors. Our two production centres are based in the towns of San Sebastián de los Reyes and Alcalá de Henares (Madrid, Spain).

InnoUp is a clinical-stage nanotechnology company focused on developing safer and more effective treatments for Food Allergies, Oncology, and Vaccines. We have developed a new drug encapsulation platform currently being tested in different clinical and pre-clinical programs. INP20 - Oral Peanut Allergy Vaccine: Phase I INP12 - Low-toxicity Paclitaxel oral chemotherapy for Breast Cancer: Phase I INP30 - Oral Vaccine Infectious Diseases: pre-clinical Our encapsulation platform is based on biocompatible nanoparticles that allow all types of payloads (drugs, proteins, RNA, and DNA). These nanoparticles have been engineered to increase bio-adhesion capacity to the mucosa, which translates into a need for lower and safer drug doses to achieve a therapeutic effect. Therefore, drugs encapsulated using our platform become more effective and safer. The technology is protected worldwide, including USA and Europe, until 2035. Our short-term business strategy includes starting operations in the US beginning 2022 with the opening of an affiliate in Boston, MA. From there, we will manage the movement to the next phases of our clinical programs (Phase II) in the US. We are already working with the FDA for the pre-IND meeting preparation. We plan to increase our value in the mid-term by building a clinical-stage multi-asset pipeline with expected significant efficacy and safety milestones by 2025. Besides, we plan to build our GMP manufacturing facility to control our manufacturing process fully. We expect it to be fully operative by 2025. We are actively working on raising money to cover the following steps and, we are open to considering all types of investment. In parallel, we are also actively seeking licensing partners interested in our products.

INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers`​ needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.

At Integra Therapeutics we have combined the precision of CRISPR systems with the gene transfer efficiency of viral integrases and transposases. Harnessing what nature has evolved to introduce large pieces of DNA into the genome, together with the precision of sequence specific DNA binding proteins, has allowed for unprecedented efficiency in programmable gene delivery.

Italfarmaco, one of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries. The company was founded in Milan in 1938. The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece, where it employs a workforce of over 1400 and has a total turnover exceeding 300 million euros. Its products, all of which have a high therapeutic content, are mainly used in the cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas.

LeadArtis is a company developing bispecific tumor targeted antibodies based on its highly innovative protein engineering platform Trimerbody®. Trimerbodies provide several advantages over conventional monoclonal antibodies, such as simultaneous multiple targeting (up to six different targets per molecule), reduced size, higher avidity for targets, and a variety of effector possibilities (immune system activation, receptor blocking, delivery of toxins or cytokines). 

 Trimerbody is a novel class of proprietary multivalent and multispecific therapeutic proteins based on specific antigen-binding domains and the unique structural and functional properties of naturally occurring collagen trimerization domains. LeadArtis’s proprietary platform allows rapid generation and production of novel biological therapeutics with potential in a wide range of human diseases. The technology was originally developed following the discovery that fully functional multivalent and multispecific antibodies could be generated by employing certain engineered collagen trimerization domains and target antigen binding domains consisting of conventional single-chain antibody fragments (scFv), single-domain antibodies or antibody mimetics. As a result, the recombinant Trimerbodies display enhanced antigen-binding capacity and are very stable. Trimerbodies, with their unique structural and functional properties, form the basis of a new generation of therapeutic molecules, which due to their small size and unique structure are ideal for the generation of novel biological drugs with multiple competitive advantages over other therapeutic molecules. LeadArtis development portfolio focusses on therapeutic areas such as immuno-oncology and inflammatory-autoimmune diseases. LeadArtis offers also licensing opportunities, offering its Trimerbody® technology to biopharmaceutical companies.

LiberaBio is a preclinical stage biotech that develops new oncology treatments based on the proprietary MPN technology. This nanotechnology actively targets tumor and metastatic cells and delivers small and large molecules to on-surface or intracellular targets. The company is creating new treatments by delivering novel antibodies targeting intracellular oncoproteins.

mAbxience is a high growth international biotechnology company specialized in the research, development, manufacture and global commercialization of biopharmaceutical products to treat and prevent diseases across different therapeutic areas.

Microviable Therapeutics is a biotech company at pre-clinical stage, developing novel biological drugs based on the microbiome to address unmet challenges in infectious diseases, oncology and dermatology. Microviable´s PharmaBiota® platform and proprietary technology has enabled to generate two different product categories, complete microbiota ecosystem products and defined bacterial consortia based on our large and diverse bacterial strain collection. Microviable´s proprietary technology and derived biological drugs have been protected through patents, trade secrets and trademarks with a growing portfolio of IP. Our lead candidate MVT-201 is a donor-derived complete microbiota ecosystem, with preclinical testing already finalized, that will enter clinical trials in 2024 for a multi-drug resistant infectious disease. Additionally, two other products are currently being developed with preliminary in vitro data available. Microviable has consolidated clinical and research international collaborations to be at the forefront of the microbiome science. Microviable is seeking to stablish collaboration agreements with pharma and biotech companies to license the biological drugs being developed, as well as other potential collaborations to further strength our capabilities in strategic therapeutic areas of interest. Microviable was incorporated in 2016, as a spinoff of the Spanish National Research Council (CSIC), founded by five prestigious research scientist and a business development person with extensive experience in pharmaceutical companies. Microviable has 10 high-qualified employees, it has received the European Seal of Excellence two times, numerous national and regional awards, and the certificate of Innovative SME. www.microviable.com

Mikrobiomik is a bio-pharmaceutical company founded to conduct research into and develop medicines based on the human microbiome. Our vision We aspire to be the first company in the world to market a medicine based on faecal microbiota in the EU. To that end, we are holding talks with both the EMA (European Medicines Agency) and the AEMPS (Spanish Agency for Medicines and Health Products) with a view to establishing protocols on the regulatory requirements for securing an MAA (Marketing Authorization Application) via centralised procedure. Our values Mikrobiomik seeks to lead the paradigm shift entailed by designing therapeutic solutions based on the human microbiome through excellence in its processes, empathising with chronic patients for whom no curative treatments are available, always from the perspective of networking with all stakeholders in the sector.

Moirai Biodesign is a pioneering RNA design company developing a novel RNA-based diagnostics platform. Our initial investigation and development aims to diagnose the cause of sepsis in the fastest, most reliable and affordable way. We are working on providing the asset which patients need the most: time.

A Biomedical Company Improving Drug Accumulation In Cancer Cells

Our mision is to improve the life of patients by designing new medicines that selectively target the cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs. We design our new drugs using state-of-the-art protein engineering and nanobiotechnology. First Project: New anti-metastatic drug Since cancer is the second cause of death worlwide, there is an urgent need for more effective and personalized treatments of tumors. Metastasis development is the main cause of patient death in most tumor types but the control of metastasis in cancer is still an unmet medical need. The current surgery-based approaches and conventional chemotherapy can be enhanced using new technologies. Our first project is a self-assembling protein nanoparticle that selectively kills metastatic cells. This nanoconjugate targets CXCR4 receptors which are over-expressed in metastatic cells of many types of cáncer. Preclinical results look very promising: in vivo results show that our drug-loaded nanoconjugate accumulates in primary tumor and metastatic foci with negible presence in liver, kidney, brain or other organs. The result is a significant decrease of the number of metastatic foci and very low toxicity on normal cells. Our focus now is to complete preclinical development in order to obtain approval for first-in-human trial.

Neuroelectrics® is a digital brain health company that innovates at the intersection of neuroscience, physics, machine learning, and hardware. We have developed wireless EEG and tDCS/tACS/tRNS stimulation devices with up to 32 channels, amongst other products encompassing software and research services, with the purpose of monitoring and enhancing brain health.

Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.

Oncomatryx is a biopharmaceutical company focused on the tumor microenvironment. Oncomatryx has developed precision drugs and diagnostic devices that target the tumor stroma. Oncomatryx Antibody-Drug Conjugates (ADCs) and human-derived proteins target peritumoral fibroblasts, endothelial cells and extracellular matrix that promote tumor invasiveness, drug resistance and immunosuppression. Oncomatryx ADCs bear novel proprietary payloads and linker derivatives that render an optimal therapeutic index against pancreatic cancer in vivo. Oncomatryx OMTX705, an ADC which targets cancer-associated fibroblasts (CAFs), inhibits pancreatic tumor growth in patient-derived xenograft mice, both as single agent and in combination with chemotherapy.

Oncostellae is a biotech startup founded in 2013 by a team of medicinal chemists and pharmacologists. The company focuses on the discovery of new pharmaceutically active compounds and their development, with a particular emphasis on small-molecule drugs with innovative scaffolds that modulate clinically validated therapeutic targets. Oncostellae is a clinical-stage biotech company that is owned by private and institutional investors, and it is involved in the discovery and development of new pharmaceutical compounds.

OneChain Immunotherapeutics is a spin-off Company from the Josep Carreras Leukemia Research Institute and ICREA, that aims to develop CAR-T candidates against different antigens as a treatment for hematological malignancies based on the know-how of Dr. Pablo Menéndez.

A shift in cancer treatment methodology makes a world of difference. Oniria Therapeutics is a spin-off from Vall d'Hebron Institute of Oncology (VHIO), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA). Oniria Therapeutics is a biotech company focused on the development of first-in-class drugs in the field of precision oncology. It develops therapies to modulate and eliminate dormant tumor cells as a novel targeted strategy to overcome their persistence. Our flagship product allosterically activates TET2, a master epigenetic enzyme.

Orikine Bio is a pioneering biotech company dedicated to advancing the field of engineered cytokines with unparalleled biological features for the treatment of immune-mediated diseases. Our core mission is to unlock the untapped potential of cytokines, enabling us to offer transformative therapies that have the power to reshape the lives of patients around the globe.

Palobiofarma S.L is a Spanish biotechnology company founded in 2006 by a group of scientists with experience in drug discovery in several pharmaceutical fields. The company is focused on developing innovative treatments for serious diseases and has been involved in various clinical trials for its most advanced compounds.

Peptomyc is a company focused on the development of a new generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment. The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research on Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.

Reig Jofre is a Spanish pharmaceutical company founded in 1929 in Barcelona. It is currently led by the third generation of the Reig family and is listed on the Spanish Stock Exchange. The company employs over 1,100 people and operates in more than 70 countries through subsidiaries and partnerships. Reig Jofre specializes in pharmaceutical manufacturing, research and development, and commercialization, with production centers located in Barcelona, Toledo, and Sweden. The company offers contract manufacturing services, focusing on sterile injectables, beta-lactam antibiotics, and lyophilized products. It has partnered with Janssen to produce the COVID-19 vaccine and collaborates on various co-development projects. Reig Jofre's product range includes antibiotics, dermatology products utilizing patented technology, hospital injectables, and over-the-counter supplements. Recent developments include the opening of a new manufacturing plant in Barcelona and expansion into the South Korean market.

Retinset is a pharmaceutical company that develops a novel class of medicines to treat ophthalmic pathologies. Our mission is to advance our portfolio to clinical trials and improve the lives of those affected by neurovascular ophthalmic pathologies.

Our aim is to develop tests that make use the full power of the complete genetic and clinical information of each patient

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Our strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators.

Smart Vitamins is a Spin-Off company from the University of Santiago de Compostela that has developed an innovative technology based in essential nutrients and nanocarriers for treating autoimmune diseases.

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.

SunRock is a biopharmaceutical company, developing sophisticated therapeutic antibodies under innovative formats antibodies to treat incurable cancer. SunRock, working under an open innovation system, aims to develop the different programs from early discovery to the completion of phase I clinical trials. SunRock has developed an extensive portfolio of bispecific molecules targeting CCR9 and HER3 raising high expectation among the key players of the industry.

Sylentis is an European biotechnological company founded in 2006. Sylentis focuses on researching new therapeutic approaches based on gene silencing. Our company is specialised in developing ophtalmologic therapies via interference RNA, a powerful tool for rational drug design. Most advanced product of the company are treatments for glaucoma and dry eye syndrome.

Telum Therapeutics SL is a global drug discovery biotechnology company specializing in the use of Innovative Phage Lytic Proteins as antibiotics.

A groundbreaking platform that extends the reach of genetic treatments by combining unprecedented DNA optimisation with non-viral delivery. Tyris Therapeutics has been founded to design the future of DNA-based treatments for patients suffering from life threatening diseases.

Headquartered in Seville, Spain, Vaxdyn works with an international network of collaborators in the development of multi-pathogen vaccines for preventing antibiotics-resistant infections in all regions of the world. Our vaccines target high-risk populations, population affected by chronic diseases of the lungs, liver, kidney, immunocompromised by co-morbidities like diabetes or cancer, populations associated with nursing homes and hospital settings, women affected by recurrent urinary-tract infections, or neonates. We are strongly committed to contribute to reducing antibiotic use in the world by following a One-Health approach. Vaxdyn is the first Spanish biotech funded by CARB-X. CARB-X awarded Vaxdyn in 2020 up to US$1.01 million, plus an additional $6.36 million if certain project milestones are met, to develop KapaVax until completion of the first proof of principle in humans (Phase 1). KapaVax is our first multi-valent candidate designed to raise immunity against Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, the top-3 superbacteria of urgent risk of the list of the World Health Organization (WHO).